A Case of Immunotherapy Response to <scp> BRAF <sup>V600E</sup> </scp> ‐Mutant Lung Adenocarcinoma With Initial Resistance to Dabrafenib and Trametinib Combination Therapy

20260 citationsJournal Articlegold Open Access

Authors

Yusuke Okayama · Fukui-ken Saiseikai Hospital

Takaaki Tokito · Kurume University Hospital

Shizuka Shiraishi · Kurume University Hospital

Reiko Takaki · Kurume University Hospital

Shingo Tsuneyoshi · Kurume University Hospital

Hiroyoshi Yamada · Kurume University Hospital

Mamoru Nishiyama

Abstract

This case suggests that ICI may provide durable clinical benefit even after early resistance to BRAF/MEK inhibition in selected patients with high PD-L1 expression.

Topics & Keywords

Melanoma and MAPK Pathways Lung Cancer Treatments and Mutations Cancer Immunotherapy and Biomarkers

Publication Details

Published in: Cancer Reports

Volume 9, Issue 4, pp. e70533-e70533

DOI: 10.1002/cnr2.70533

Field-Weighted Citation Impact: 0.00

Command Palette

A Case of Immunotherapy Response to <scp> BRAF <sup>V600E</sup> </scp> ‐Mutant Lung Adenocarcinoma With Initial Resistance to Dabrafenib and Trametinib Combination Therapy

Authors

Abstract

Topics & Keywords

Publication Details